Deerfield Management & Brookside Capital Revealed Significant Stakes in Newly Public Dicerna Pharmaceuticals Inc (DRNA)

In a couple of filings with the Securities and Exchange Commission, Deerfield Management, led by James E. Flynn, and Bain Capital’s Brookside Capital reported holding stakes in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), a company that went public a couple of days ago.  Deerfield disclosed holding a total of  2.42 million common shares of the company, while Brookside’s stake amasses 2.34 million shares.

Deerfield obtained the securities through the conversion of around 1.43 million Series C Preferred Stock and the acquisition of additional shares at a price of $15 apiece.

Dicerna Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), a biopharmaceutical company that focuses on treating rare inherited diseases related to the liver and for cancer, offered 6.0 million shares in its initial public offering at a price of $14.0 per share.

The company has partnered with Kyowa Hakko Kirin Co., Ltd. (KHK) for two of its oncology development programs. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) expects to receive clinical, regulatory and commercialization milestone payments for each of its product candidate under research collaboration and license agreement with KHK, of up to $110.0 million.

RA Capital Healthcare Fund, an affiliate fund of the Peter Kolchinsky‘s Ra Capital Management is also a significant shareholder of Dicerna, holding around 1.43 million shares prior to the IPO.

Deerfield Management focuses on investment companies that specialize in managing hostile takeovers, funding R&D, corporate transitions and financial advisory services.

A couple of months ago, Deerfield Management initiated a passive stake in Horizon Pharma Inc (NASDAQ:HZNP), and revealed owning 4.4 million shares. It also upped its stake in Universal American Corporation (NYSE:UAM) to 4.4 million shares, from 2.9 million shares, and boosted its position in Capital Senior Living Corporation (NYSE:CSU) to 1.8 million shares from 1.1 million shares held earlier.

Brookside Capital is a long/short public equities fund, using fundamental analysis as well as industry and competitive, it invests across all economic sectors.

Brookside Capital held 2.28 million shares of Monsanto Company (NYSE:MON) at the end of the third quarter of 2013. The fund was also bullish on Youku Tudou Inc (ADR) (NYSE:YOKU), and held 8.15 million shares at the end of the third quarter.

Disclosure: none

Recommended reading:

Michael Messner’s Seminole Capital Top Picks From the Latest 13F

Hedge Fund Highlights: Jeffrey Altman, Seth Klarman & Ken Griffin

Sanford J. Colen Sends Letter To Board of MicroStrategy (MSTR); Wants Investor Communication Program

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!